• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes.

作者信息

McGarry Brian E, Sommers Benjamin D, Wilcock Andrew D, Grabowski David C, Barnett Michael L

机构信息

Department of Medicine, University of Rochester, Rochester, New York.

Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.

出版信息

JAMA. 2023 Aug 8;330(6):561-563. doi: 10.1001/jama.2023.12945.

DOI:10.1001/jama.2023.12945
PMID:37450293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10349351/
Abstract
摘要

相似文献

1
Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes.美国养老院中新型冠状病毒肺炎感染的单克隆抗体和口服抗病毒治疗
JAMA. 2023 Aug 8;330(6):561-563. doi: 10.1001/jama.2023.12945.
2
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.在真实世界环境中探索使用单克隆抗体和抗病毒疗法对 COVID-19 门诊患者进行早期治疗：来自英国和意大利的全国性研究。
BioDrugs. 2023 Sep;37(5):675-684. doi: 10.1007/s40259-023-00601-w. Epub 2023 May 6.
3
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.社论：非住院患者 SARS-CoV-2 感染的口服抗病毒药物治疗现状。
Med Sci Monit. 2022 Jan 1;28:e935952. doi: 10.12659/MSM.935952.
4
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.SARS-CoV-2：感染引起的免疫反应和疫苗及治疗的发展。
Front Immunol. 2020 Dec 11;11:569760. doi: 10.3389/fimmu.2020.569760. eCollection 2020.
5
Antiviral monoclonal antibody cocktails as a modern weapon in combating pandemics.抗病毒单克隆抗体鸡尾酒疗法作为对抗大流行的现代武器。
Ther Deliv. 2022 Feb;13(2):67-69. doi: 10.4155/tde-2021-0079. Epub 2021 Nov 2.
6
Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19.从过去的失败中吸取教训：COVID-19 单克隆抗体疗法面临的挑战。
J Control Release. 2021 Jan 10;329:87-95. doi: 10.1016/j.jconrel.2020.11.057. Epub 2020 Dec 1.
7
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.免疫功能低下患者持续性或复发性严重急性呼吸综合征冠状病毒 2 感染的 2 种抗病毒药物和单克隆抗体三联疗法。
Clin Infect Dis. 2023 Jul 26;77(2):280-286. doi: 10.1093/cid/ciad181.
8
Oral antivirals for acute symptoms and post-acute sequelae in SARS-CoV-2 infection.用于治疗新型冠状病毒感染急性症状和急性后遗症的口服抗病毒药物。
Lancet Infect Dis. 2024 Oct;24(10):1066-1067. doi: 10.1016/S1473-3099(24)00258-5. Epub 2024 May 3.
9
COVID-19 Updates: Monoclonal Antibodies for COVID-19.新冠疫情最新消息：用于治疗新冠的单克隆抗体
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16.
10
Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients.COVID-19 儿科患者单抗治疗的安全性和耐受性。
Pediatr Infect Dis J. 2021 Dec 1;40(12):e507-e509. doi: 10.1097/INF.0000000000003263.

引用本文的文献

1
Racial Inequities and Access to COVID-19 Treatment.种族不平等与获得新冠病毒治疗的机会
JAMA Netw Open. 2025 Jul 1;8(7):e2518459. doi: 10.1001/jamanetworkopen.2025.18459.
2
Prevalence and healthcare burden of inappropriate antimicrobial treatment in patients at high risk of complications from acute respiratory infections: a scoping review.急性呼吸道感染并发症高危患者不适当抗菌治疗的患病率及医疗负担：一项范围综述
Front Med (Lausanne). 2025 May 16;12:1533797. doi: 10.3389/fmed.2025.1533797. eCollection 2025.
3
Kinetics of SARS-CoV-2 Shedding in Nursing Home Residents and Staff.养老院居民和工作人员中新型冠状病毒2型脱落的动力学
J Am Geriatr Soc. 2025 Jul;73(7):2127-2136. doi: 10.1111/jgs.19499. Epub 2025 May 2.
4
Measures to Prevent and Control COVID-19 in Skilled Nursing Facilities: A Scoping Review.专业护理机构中预防和控制新冠病毒病的措施：一项范围综述
JAMA Health Forum. 2025 Jan 3;6(1):e245175. doi: 10.1001/jamahealthforum.2024.5175.
5
Nirmatrelvir/Ritonavir (Paxlovid) Use Among Individuals at Risk of Severe COVID-19: An Analysis of the National COVID Cohort Collaborative (N3C).尼马曲韦/利托那韦（帕克洛维德）在有重症 COVID-19 风险的个体中的使用：国家 COVID 队列协作（N3C）的分析。
Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5869. doi: 10.1002/pds.5869.
6
Perceived Risk for Severe COVID-19 and Oral Antiviral Use Among Antiviral-Eligible US Adults.美国符合使用抗病毒药物条件的成年人中对重症 COVID-19 的感知风险及口服抗病毒药物的使用情况
Infect Dis Ther. 2024 Aug;13(8):1743-1757. doi: 10.1007/s40121-024-01003-3. Epub 2024 Jun 23.
7
Screening Strategies to Reduce COVID-19 Mortality in Nursing Homes.养老院降低 COVID-19 死亡率的筛查策略。
JAMA Health Forum. 2024 Apr 5;5(4):e240688. doi: 10.1001/jamahealthforum.2024.0688.
8
Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System.在国家退伍军人事务（VA）医疗系统中，使用奈玛特韦/利托那韦治疗非住院的新冠肺炎成年患者。
Infect Dis Ther. 2024 Jan;13(1):155-172. doi: 10.1007/s40121-023-00910-1. Epub 2024 Jan 13.
9
Underuse of SARS-CoV-2-Neutralizing Monoclonal Antibodies in Skilled Nursing Facilities.《在熟练护理机构中 SARS-CoV-2 中和单克隆抗体的未充分使用》
J Am Med Dir Assoc. 2024 Feb;25(2):290-295. doi: 10.1016/j.jamda.2023.10.003. Epub 2023 Nov 6.
10
Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study.SLE 患者抗 SARS-CoV-2 抗病毒药物和单克隆抗体的疗效和安全性：一项病例对照研究。
Biomolecules. 2023 Aug 22;13(9):1273. doi: 10.3390/biom13091273.